GlassScriptPhysician profile
James P Wade
NPI 1386640399
$13,695.21
in general payments reported to CMS, 2019-2025
68 companies · $2,920 in 2025
The $2,920 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,258 · 2020: $1,499 · 2021: $1,136 · 2022: $1,449 · 2023: $719 · 2024: $1,714 · 2025: $2,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,295 · Education: $58.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,295.33 |
| Education | $58.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,829.31 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,547.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,011.23 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $823.79 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Teva Pharmaceuticals USA, INC. | $633.11 | 2019-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Lilly USA, LLC | $572.49 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Allergan, INC. | $531.91 | 2019-2020 | |
| Amgen INC. | $481.34 | 2019-2025 | Repatha, Otezla, Repatha |
| Intuitive Surgical, INC. | $442.50 | 2025 | |
| Astellas Pharma US INC | $432.88 | 2019-2025 | Veozah, Xtandi, Xospata |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $363.30 | 2019-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $334.33 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $327.31 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $276.95 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $275.85 | 2019-2025 | Spravato, Xarelto |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wade listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.